Oral drug absorption enhancement by chitosan and its derivatives

被引:597
作者
Thanou, M [1 ]
Verhoef, JC [1 ]
Junginger, HE [1 ]
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Pharmaceut Technol, NL-2300 RA Leiden, Netherlands
关键词
chitosan; absorption enhancers; peptide drugs; low molecular weight heparin; trimethyl chitosan chloride (TMC); monocarboxymethylated chitosan (MCC);
D O I
10.1016/S0169-409X(01)00231-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chitosan is a non-toxic, biocompatible polymer that has found a number of applications in drug delivery including that of absorption enhancer of hydrophilic macromolecular drugs. Chitosan, when protonated (pH < 6.5), is able to increase the paracellular permeability of peptide drugs across mucosal epithelia. Chitosan derivatives have been evaluated to overcome chitosan's limited solubility and effectiveness as absorption enhancer at neutral pH values such as those found in the intestinal tract. Trimethyl chitosan chloride (TMC) has been synthesized at different degrees of quaternization. This quaternized polymer forms complexes with anionic macromolecules and gels or solutions with cationic or neutral compounds in aqueous environments and neutral pH values. TMC has been shown to considerably increase the permeation and/or absorption of neutral and cationic peptide analogs across intestinal epithelia. The mechanism by which TMC enhances intestinal permeability is similar to that of protonated chitosan. It reversibly interacts with components of the tight junctions, leading to widening of the paracellular routes. Mono-carboxymethylated chitosan (MCC) is a polyampholytic polymer, able to form visco-elastic gels in aqueous environments or with anionic macromolecules at neutral pH values. MCC appears to be less potent compared to the quaternized derivative. Nevertheless, MCC was found to increase the permeation and absorption of low molecular weight heparin (LMWH; an anionic polysaccharide) across intestinal epithelia. Neither chitosan derivative provokes damage of the cell membrane, and therefore they do not alter the viability of intestinal epithelial cells. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 57 条
[21]   Effect of chitosan on epithelial permeability and structure [J].
Dodane, V ;
Khan, MA ;
Merwin, JR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (01) :21-32
[22]  
Duizer E, 1998, J PHARMACOL EXP THER, V287, P395
[23]   Innovative strategies for the oral delivery of drugs and peptides [J].
Fasano, A .
TRENDS IN BIOTECHNOLOGY, 1998, 16 (04) :152-157
[24]   ACYLCARNITINES - DRUG ABSORPTION-ENHANCING AGENTS IN THE GASTROINTESTINAL-TRACT [J].
FIX, JA ;
ENGLE, K ;
PORTER, PA ;
LEPPERT, PS ;
SELK, SJ ;
GARDNER, CR ;
ALEXANDER, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 251 (03) :G332-G340
[25]   DIRECT ASSOCIATION OF OCCLUDIN WITH ZO-1 AND ITS POSSIBLE INVOLVEMENT IN THE LOCALIZATION OF OCCLUDIN AT TIGHT JUNCTIONS [J].
FURUSE, M ;
ITOH, M ;
HIRASE, T ;
NAGAFUCHI, A ;
YONEMURA, S ;
TSUKITA, S ;
TSUKITA, S .
JOURNAL OF CELL BIOLOGY, 1994, 127 (06) :1617-1626
[26]   THE BLOOD COMPATIBILITY OF CHITOSAN AND N-ACYLCHITOSANS [J].
HIRANO, S ;
NOISHIKI, Y .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1985, 19 (04) :413-417
[27]  
HOCHMAN JH, 1994, J PHARMACOL EXP THER, V269, P813
[28]  
Illum L, 1998, PHARM RES-DORDR, V15, P1326
[29]   CHITOSAN AS A NOVEL NASAL DELIVERY SYSTEM FOR PEPTIDE DRUGS [J].
ILLUM, L ;
FARRAJ, NF ;
DAVIS, SS .
PHARMACEUTICAL RESEARCH, 1994, 11 (08) :1186-1189
[30]   Macromolecules as safe penetration enhancers for hydrophilic drugs - a fiction? [J].
Junginger, HE ;
Verhoef, JC .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (09) :370-376